MD Anderson and Blueprint Medicines announce strategic collaboration to accelerate BLU-222 development
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year strategic research collaboration focused on accelerating development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 (CDK2).
The collaboration brings together MD Anderson translational research scientists, the drug development capabilities of MD Anderson’s Therapeutics...
MD Anderson and Hummingbird Bioscience announce strategic research collaboration to advance innovative immunotherapies
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience today announced the launch of a multi-year strategic research...